Completed
Phase II study of TNX-355 with optimized background therapy
A phase II, multicentre, randomized, double-blind, placebo-controlled, three-Arm study of the anti-CD4 monoclonal antibody TNX-355 with optimized background therapy in treatment-experienced subjects infected with HIV-1. (TNX-355.03)
Learn More